Trades of Eli Lilly shares were made on Trump’s behalf as drugmaker benefitted from his policies

Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies

Hundreds of thousands of dollars was invested in Eli Lilly on Donald Trump’s behalf earlier this year, according to financial disclosures, as the US drugmaker benefited from his administration’s bid to expand access to blockbuster obesity treatments.

Ethics filings revealed several thousand trades on the US president’s behalf tied to stocks and bonds in the first quarter of 2026, with a cumulative ​value of between $220m and around $750m.